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Abstract
Versatile yet biocompatible bio-materials are in high demand in nearly every 
industry, with biological and biomedical engineering relying heavily on common 
biomaterials like alginate polymers. Alginate is a very common substance found in 
various marine plants which can easily be extracted and purified through cheap 
nonhazardous methods. A key characteristic of alginate polymers includes easily 
manipulatable physical properties due to its inert but functional chemical composi-
tion. Factors including its functional versatility, long-term polymer stability and 
biocompatibility have caused alginate-based technologies to draw major attention 
from both the scientific and industrial communities alike. While also used in food 
industry manufacturing and standard dental procedures, this chapter will focus on 
a discussion of the both clinical and nonclinical use of alginate-based technologies 
in transplantation for regenerative cell and drug delivery systems. In addition, we 
overview the immune system response prompted following implantation of alginate 
hydrogels. Consequences of immune cell reactivity to foreign materials, such as 
inflammation and the foreign body response (FBR), are also analyzed and current 
and future strategies for potential circumvention of severe immune responses 
toward alginate-based devices are reviewed and suggested.
Keywords: alginate, biomaterial, foreign body response, inflammation, 
transplantation, pancreatic islet, stem cell, microencapsulation
1. Introduction
Alginate was first described in the 1880s by the British chemist E.C.C Stanford 
after extracting it from seaweed using a rudimentary ion exchange method [1]. 
After the commencement of commercial production in the late 1920s, alginate 
became a widely used substance in several industries due to it numerous useful 
and nontoxic attributes. By the middle of the twentieth century, alginate was a 
major contributor to the food industry as a food-stabilizer. Today, Alginate-derived 
products contribute to the seaweed industry which had an annual production value 
of over $4.1 billion USD in 2017 [2].
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2. Sources of alginate
2.1 Brown algae source
Contributing up to 40% of the dry matter, a major raw source of alginic acid is 
derived from marine algae and kelp-like brown seaweed [3, 4]. There are several 
species of brown algae from which alginate can be derived; however, two species, 
namely Macrocystis porifera and Ascophyllum nodosum, account for most of the 
world’s supply of alginate [5]. These species of seaweed are members of a class of 
seaweed that are both large and lengthy, making these plants ideal for alginic acid 
harvesting [5]. Unlike eukaryotic animal cells, plant cells are known to contain a 
rigid cell wall composed mainly of carbohydrate polysaccharide like cellulose and 
pectin [6]. Marine plants, such as algae, contain cell walls which are maintained by 
hydrocolloid polysaccharides such as alginate, carrageen, and agar which differ-
entiate aquatic vegetation from land plants [6, 7]. These precursors can be used to 
cultivate alginic acid for market production.
2.2 Bacterial exopolysaccharide alginate source
Two types of gram-negative bacteria genera, namely Pseudomonas and 
Azotobacter, can produce alginate in the form of exopolysaccharides which consti-
tute bacterial biofilm [8, 9]. For example, Pseudomonas aeruginosa can synthesize 
alginate which contributes to the mucosal buildup of biofilms along the respiratory 
tract of patients with the disease cystic fibrosis [10–12]. The biosynthesis of algi-
nate in these bacteria genera are conducted through genetic expression of alginate 
substrate producing genes (alg), the products of which are exported to the cell 
exterior [9]. The isolation of marginally pure alginate from immobilized bacterial 
cell extracts has been reported, but the progress of advanced bacterial alginate 
isolation techniques has been slow overall [13, 14]. Although these bacteria can be 
utilized as a source of alginate, the main commercially available form of alginate is 
derived from brown algae sources.
2.3 Alginate extraction
Alginate exists in vivo as a mixture of different alginate salts including mag-
nesium, strontium, or calcium within the intracellular matrix of brown algae 
tissue [4, 15]. Alginate is the conjugate base of the alginic acid and is formed 
upon treatment with alkaline medium [4, 16]. The primary extraction of alginic 
acids from brown seaweed is performed using an alkaline ion exchange treatment 
method which can extract and separate each of the major carbohydrate constitu-
ents of the brown algae [8, 17]. The initial extraction of algal particles from brown 
algae results in semi-pure fractions of differing polysaccharides which include 
the salt form of alginate [18, 19]. A chemical purification process, usually CaCl2 
purification, involves treatment of algal particles with a mineral acid followed 
by neutralization with strong base (Figure 1). Alginate precipitates are formed 
via further ion transfer acid-base reaction which results in a product of mainly 
sodium alginate [4, 8, 18]. The sodium alginate form of alginic acid is the most 
favored form produced after extraction which is mainly due to cold water solubil-
ity [16]. Current techniques examine the quality and purity of extracted alginate 
during extraction and purification processes through several chemistry-based 
analytical assays including nuclear magnetic resonance (NMR) and infrared (IR) 
spectroscopy [16, 20]. Recent advances in computational modeling have allowed 
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researchers to construct models of precipitation stages which has allowed for 
optimization of the extraction and purification process overall [20].
3. Composition of alginate
3.1 Types of alginate polymers
Alginate is an unbranched copolymer of β-d-mannuronic acid (M group) and 
α-l-guluronic acid (G group) commercially derived from algae [8]. Hydroxyl and car-
boxyl groups are abundantly distributed across the polymer, giving rise to a plethora 
of chemically modifiable sites [21]. Commercially, alginate is blocked in either 
consecutive M, consecutive G, or alternating M & G [22]. Given that it is a polymer 
with versatile properties, alginate can be easily changed to exhibit a variety of proper-
ties tailored to the individual needs of an implant. Pre-existing properties of alginate 
are able to be chemically enhanced through manipulating the percentage of M and 
G in the material, adding immunoprotective layers that impede diffusion, as well as 
divalent cation crosslinking. Under dicationic conditions, viscous alginate transforms 
Figure 1. 
Extraction of sodium alginate from brown seaweed followed by sodium alginate purification via CaCl2 
purification.
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into a gel, which can then be used as an encapsulation medium for islet cells [23–25]. 
M groups lie with the main ring in an equatorial conformation, with each mer con-
nected covalently through an ether (Figure 2). With dications situating on top and on 
bottom of each layer, a “swelling” effect is noted as there is no discrete pocket between 
mers resulting in each linear polymer stacking on top of the crosslinking dication. 
In contrast, G groups lie with the main ring axial (Figure 3). These mers are also 
attached through an ether. However, these ethers create pockets large enough for dica-
tions to situate without creating a swollen stacking effect. Manipulation of molecular 
weight and composition (%G or %M) leads to varying strength and porosity of the 
gel [26, 27]. Generally, alginates with higher %G have higher comparative levels of 
elasticity and stability [22].
Along with Macrocystis porifera and Ascophyllum nodosum, another type of 
brown seaweed that is a main source of alginate is called Sargassum polycystum 
C. Agardh. One study extracted alginate from S. polycystum to examine its chemical 
makeup and viscosity in the leaf, stem and thallus regions [28]. Thallus of seaweed 
refers to undifferentiated tissues where nutrient uptake and gas exchange occurs 
[29]. Of the structures studied for S. polycystum, the leaf region was found to have 
the highest alginate yield followed by the stem region and the thallus [28]. In con-
trast, the viscosity of alginate was highest in the stem region, followed by the leaf 
region and thallus [28]. Of the M/G ratios observed, the stem region had the lowest 
M/G ratio and the highest level of G-block content, optimal properties of forming 
a rigid and stable gel [28]. Similarly, other commercial brown seaweeds such as the 
stems of Laminaria hyperborea have a high G-block content (70%) and a low M/G 
ratio (0.43) [30].
3.2 UPLVM
Purified alginate containing almost entirely M blocks with little to no G blocks 
will typically not yield the ideal type of hydrogel desired through dication cross-
linking. The lack of pockets available for crosslinking will result in a form of layers 
of alternating alginate polymers and dications. In terms of structural integrity, 
UPLVM alginate will be less porous and strong, allowing higher malleability. In 
addition, although there has been no clear consensus, studies have suggested that 
a greater percentage of M blocks in alginate cause an increased immune response 
compared to UPLVG alginate, as indicated by increased production of TNF-⍺, IL-1 
and IL-6 [31].
3.3 UPLVG
Alginate with a higher %G blocks (>60% G) will result in a material a higher 
polymer strength and available crosslinking sites for barium atoms [27]. Since 
there are sites for divalent cation network crosslinking, the cations will situate 
themselves in the “egg carton” that the G blocks form. The cations in this position 
Figure 2. 
Chemical structure of M-block monomer.
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create a resistance to shear and frictional forces that the layers undergo as alternat-
ing molecular weight increases [32]. Therefore, this orientation allows for higher 
density, strength and porosity. The carboxylate anions that lie equatorial in G 
blocks are usually protonated under acidic conditions, which are deprotonated as 
the basicity of the solution increases [33]. The alcohol groups also present in the 
polymer provide a hydrogen that is capable of being deprotonated in basic condi-
tions. Although this pH change resistance results in an increased stability of G-rich 
polymers against depolymerization, pH changes in solution will result in swelling of 
alginate capsules [34].
3.4 Mixtures
Alginate is commercially sold as a mixture of M & G blocks with varying 
purification. NovaMatrix in Norway is a widely used company that manufactures 
and distributes purified alginates [34]. Their UP LVG (ultrapure low viscosity, 
high G) alginate has at least a 1.5:1 ratio of G:M blocks, with UP LVM (ultrapure 
low viscosity, high M) alginate having a ratio of G:M of less than 1. NovaMatrix 
recommends a shelf life of 5 years for their UP LVG alginate while only 3 years 
for UP LVM alginate. Both types of alginate should ideally be stored in a fridge 
and maintained at a relatively neutral pH (between 5 and 8) so as to decrease the 
rate of depolymerization. Higher temperatures will result in an increased rate of 
polymerization, which is expanded even further in the presence of an acid or a 
base. A neutral pH will prevent acid or base catalysts from recruiting oxygen to 
initiate oxidative-reductive depolymerization. Both M-rich and G-rich alginates 
react with no significant difference when base catalyzed, but M-rich alginates are 
hypothesized to be more vulnerable to acid catalyzed depolymerization, as sup-
ported by a catalytic constant that is twice as large for M-rich alginates than that 
of G-rich alginates [35]. In addition, in the presence of oxygen and an acidic or 
alkaline environment, the phenol and carboxylate groups will react in undesired 
ways, resulting in free radical depolymerization.
3.5 Alginate derivatives
Alginate derivatives have also been created to encompass certain properties. 
One example of this is amphiphilic alginate derivatives that utilize the alginate 
backbone and synthesize it with hydrophobic moieties [8, 36]. An example of this 
is sodium alginate being conjugated with long alkyl chains via ester bonds [36]. The 
microparticles for the derivative are prepared using dispersion in a sodium chloride 
solution; this allows for encapsulation of proteins and their subsequent release by 
adding surfactants to disrupt intermolecular hydrophobic junctions or esterases 
that hydrolyze the ester bond between the alginate backbone and alkyl chains 
[36]. Other types of derivatives include dodecylamine conjugated to an alginate 
backbone via amide linkage which leads to long-term stability in aqueous media 
compared to other alginate derivatives composed of dodecyl esters which have 
Figure 3. 
Chemical structure of G-block monomer.
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a risk of hydrolysis [36]. Amphiphilic alginate derivatives that are water soluble 
have also been developed using cholesteryl groups which are synthesized using 
N,N′-dicyclohexylcarbodiimide as a coupling agent and 4-(N,N′-dimethylamino)
pyridine as a catalyst at room temperature [37]. Other derivatives include cell-
interactive alginates which are composed of cell-adhesive peptides. To prepare 
these, carbodiimide chemistry is used to combine peptide side-chains with carbox-
ylic groups on sugar molecules [36]. This is important because alginate must acquire 
the proper ligands to participate in cell-to-cell interactions since it does not innately 
have cell-adhesivity to mammalian cells [36]. The peptide sequence arginine-
glycine-aspartic acid (RGD) has been studied widely due to the copious integrin 
receptors for this ligand on a variety of cell types [38]. This, among other types of 
cell-interactive alginates, has been used for scaffolds for tissue engineering and 2-D 
and 3-D cell culture matrices.
4. Current biotechnological uses
4.1 Food industry applications
The alginate industry saw increases in production in response to the scientific 
advancements in the study of alginate properties and potential uses [39]. Currently, 
the FDA classifies alginate as meeting the guidelines of the Food Chemical Codex 
and lists over seven different uses of it in the food industry [40]. The primary 
market for alginate in the processed food market where they serve as texturing 
agents and food stabilizers [41]. The gel-like chemical properties, which are safe 
for consumption, also allow for several other uses such as increasing storage life of 
potatoes, immobilization of banana enzymes, immobilization of lactic acid bacte-
ria, and fillers in meat and fish products [39, 42]. The ability of alginate hydrogel 
to be polymerized, or gelled, into a microcapsule with a hollow core has led to the 
development of food encapsulation technologies aimed at food preservation [42]. 
Recently, researchers have shown that application of an alginate coating on egg 
shells has led to the elimination of cross-contamination from Salmonella enteritidis 
for up to 42 days [43]. Currently in the beverage industry, alginate is used as an 
emulsifying agent to maintain the stability of foam within beverages like beer [44, 
45]. Continued use in the food industry will likely increase the commercial demand 
of alginate in the future.
4.2 Pancreatic islet cell-delivery system
In 1933, Biscegeli implanted polymer matrix coated murine-derived tumor cells 
in to the abdomen of guinea pigs which remained viable without rejection, thus 
discovery prompted entire fields to research into microencapsulation technolo-
gies [46]. Several advances in biotechnological approaches to both cell microen-
capsulation and the development of drug delivery systems using alginate have 
been achieved for nearly 50 years [47]. When reconstituted in aqueous solution, 
alginate forms a hydrogel which in the presence of polyvalent cation (e.g., Ba2+, 
Ca2+, Sr2+) reorganizes into a rigid biomaterial [4]. Alginate hydrogels can be used 
to encapsulate cellular tissue and nonliving substances for therapeutic cellular-
delivery as a treatment to many diseases such as Type 1 Diabetes [48]. Xenograft 
transplantations for type 1 diabetes heavily rely on alginate hydrogels as a source 
biomaterial for encapsulation of porcine pancreatic islets. Key obstacles observed 
with porcine islet xenograft include possible transmission of hemagglutinating 
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and lymphocytotoxic antigens, such as carbohydrate α-(1,3)-galactose, which are 
a major contributor to acute host immune rejection [49–51]. Alginate encapsula-
tion, in contrast to other biomaterials, reduces transmission of humoral immune 
response elements while allowing for the transport of nutrients and export of 
insulin across the semipermeable barrier [52]. Recently, alginate-encapsulated APIs 
were transplanted intraperitoneally into STZ-induced IDDM nonhuman primates. 
Nonhuman primates exhibited a marked decrease in exogenous insulin demands 
and lower %HbA1C in addition to normalized blood glucose values for 20–70 days. 
However, the glycemic control was reduced over time, which they concluded was 
due to decreased graft function and viability [53].
4.3 Stem cell-delivery system
With the application of FDA regulations and recent advances in stem cell-related 
technologies, there has been an increase in need for viable targeted delivery system 
for therapeutics [54–57]. The biocompatibility and relative ease of production 
of alginate hydrogels makes alginate an important candidate for production of 
immune-isolated stem cell delivery systems [8, 58, 59]. A major disease model 
currently researching stem cell-related therapies is for the treatment of type 1 
diabetes, among insulin-dependent conditions. Recently, insulin-producing human 
SC-derived β-cells encapsulated with alginate polymers were implanted in immune-
competent mice. Multiple studies report glycemic control with immuno-isolated 
β-cells in mice, some resulting in up to 174 days of glycemic correction, in addition 
to detection of human C-peptide in mouse serum [60, 61]. A 2019 study showed 
similar results after transplanting human pluripotent stem cell-derived (iPSCs) 
β-cells into immunocompetent mice which resulted in glycemic control for more 
than 150 days [62]. Other disease models have also used alginate microencapsula-
tion for therapeutic use of xenogeneic stem cell-delivery. Researchers have reported 
functional alginate encapsulated adrenal SCs for use in adrenal hormone insuf-
ficiency diseases [63, 64]. Successful alginate encapsulation of neural embryonic 
stem cells was also reported for targeted cell-delivery serving possible treatment for 
neural tissue repair in several neurological disorders [65]. Microencapsulation of 
stem cells is a very active field of research and advances with this technology have a 
wide range of clinical applications.
4.4 Cryoprotective use of alginate microencapsulation
Transplantations can sometimes rely heavily on transportation or storage of 
tissues before the procedure. Cryopreservation, known as a viable option for tissue 
preservation and storage, can have severe effects on the viability and function of 
tissues during the freezing/thawing processes and from use of cryoprotective agents 
[66]. Alginate microcapsules have demonstrated the ability to maintain structure, 
slow cooling process, reduce effects of ice crystal formation on tissue, and regulate 
influx of cryoprotective agents during cryopreservation [67, 68]. First used in preser-
vation of plant cells, use of an alginate coating has been observed to have cryoprotec-
tive properties [69–72]. Success with plant cell preservation catalyzed the research 
into alginate cryoprotective potential with other tissue types. Alginate coatings of 
beneficial probiotic bacteria have demonstrated maintenance of viability and func-
tion through the cryopreservation process which has potential applications in yogurt 
and probiotic preservation [73–75]. An augmented necessity of tissue preservation 
methods has caused a rise in research related to cryopreservation for storage and 
distribution of animal cells. Alginate microencapsulation of cells offers significant 
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degree of cryoprotection during cryo processing [76, 77]. Transplantation research 
has particularly benefited from use of alginate technologies during cryopreserva-
tion. Recent studies in pancreatic islet transplantation have demonstrated that use of 
alginate microencapsulation helps maintain islet viability during preservation and 
improves islet secretory function during transplantation [67, 78, 79]. A 10 years study 
using encapsulated rat, pig, human islets showed that alginate encapsulated islets 
maintained significantly higher viability, secretory function, and yield compared to 
nonencapsulated islets after cryopreservation for 10 years [80]. Like pancreatic islets 
grafts, cryopreservation is also used for preservation of stem cells before transplanta-
tion. Alginate encapsulation has been shown repeatedly to improve both yield and 
function of multiple stem cell lines, including human stem cells [81, 82]. Recently, the 
use of alginate microcapsules improved viable recovery of human adipose-derived 
stem-cells after 72-h storage in hypothermic conditions [83]. The overall benefits of 
cryoprotection via alginate encapsulation will ensure relevance in future research of 
cell preservation and transplantation.
4.5 Conjugated alginate potential as drug-delivery system
Due to the relative feasibility of conjugation and semi-permeable wall struc-
ture of alginate microcapsules shows promising secretory capabilities for robust 
nanoparticle drug-delivery systems [8, 84–86]. Recently researchers have been 
able to conjugate alginate microcapsules with anti-HIV zidovudine nanoparticles. 
Results showed significant improvements in internalization of the nanoparticle 
into glioma cells during in vitro experiments marking for potential use as a targeted 
viral drug delivery system [87]. Another study demonstrated the conjugation of 
sodium alginate with graphene oxide which is known to create functional groups 
for synthesis. GO-conjugated alginate hydrogels readily loaded the anticancer drug 
oxorubicin hydrochloride (DOX·HCl) and caused high cytotoxicity when exposed 
to immortal HeLa cell lines [88]. When islet containing alginate microcapsules were 
conjugated with VEGF, increases in angiogenesis, islet viability, and islet function 
were observed [89]. More recently, similar benefits were observed through increases 
in bone formation and blood vessel growth after biomineral-conjugated alginate 
microcapsules containing MSCs were transplanted into sheep with ovine iliac crest 
bone defects [90]. The versatile conjugation behavior of alginate hydrogels has 
impressive potential for a variety of future medical applications in transplantation.
5. Immune response
5.1 Alginate purity effect on immunogenicity
Crude unpurified alginate has been shown to provoke the immune system which 
then causes fibrosis around the microcapsule [91]. This overgrowth of immune-
cells and fibroblasts interferes with the transfer of nutrients, hormones, and other 
proteins via the semi-permeable membrane of the capsule [92]. This is a difficult 
problem to avoid especially since the industrial processing used for extraction can 
leave contaminates in the alginate like polyphenols, endotoxins and algal proteins 
[92, 93]. Purification is a technique utilized to minimize the amount of contamina-
tions in the alginate gels. Commercially available sodium alginate can be purchased 
in several different purified states including “ultra-purified” form from companies 
like Novamatrix® for use in hydrogel production [94–96]. Although this is highly 
purified there are still small concentrations of contaminants in the alginate that 
can prompt a severe foreign body response [91, 97]. If the alginate biomaterials 
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hold living tissue within a drug-delivery system, the foreign body reaction tends to 
reduce the survivability of those tissues [92, 98].
5.2 Inflammation and the foreign body response
The human immune system is broken into two parts, the innate and adaptive 
immune systems, which both work in tandem to defend and destroy external bac-
teria, viruses and various other microbes that may infiltrate a host’s body [99]. The 
first aspect of the foreign body response (FBR) is the innate immune system which 
has no flexibility or memory to foreign antigens. This is followed by the adaptive 
immune system which generates a custom response to each specific pathogen while 
simultaneously building an immunological memory [92]. Alginate hydrogels used 
in implantations are highly purified so as to not present antigens on their surface 
and thus should not cause T cell activation due to antigen-presentation [100]. 
Despite lacking these immunoreactive properties, within nanoseconds of entering a 
host, biomaterials initiate an inflammatory FBR due to biomaterial surface interac-
tions with tissue, proteins, and blood [100, 101]. The foreign body response results 
in fibrotic overgrowth surrounding the implanted alginate hydrogels which essen-
tially isolates the biomaterial from host’s body [102]. This fibrotic overgrowth is 
initiated by a sequence of cascading events including injury formation, recruitment 
of immune cells and fibroblasts, and cell adhesion which leads to fibrous tissue 
deposition [103]. Two stages of inflammation, namely acute followed by chronic, 
facilitate the foreign body response once alginate biomaterials are implanted [102].
It was determined that the immunogenic properties of alginate polymers were 
not directly responsible for the overgrowth around capsules but do contribute 
to is formation. In order for the immune cells to adhere to the cell surface, there 
must be a significant amount of protein adsorption or anchor sites for immune cell 
adhesion [92, 102]. Instead, the immune response occurs in the tissue immediately 
surrounding the alginate structure [92]. Studies have demonstrated that within a 
few days after alginate biomaterial implantation into animals, immune cells and 
differentially activated macrophages (i.e., stadia, granulocytes, and basophils) 
collect around, but not on, the alginate surface [92, 104]. This acute inflammatory 
period is characterized by the recruitment of macrophages and neutrophils in 
addition to the release of histamine and fibrinogen adsorption from mast cells to 
surrounding tissue [92, 102]. This is all done without significant immune cell adhe-
sion to alginate biomaterials. A key player in immune cell recruitment are pattern 
recognizing receptors (PRRs) which act as sensors on cells of the innate immune 
system by responding to evolutionary conserved molecules with can contaminate 
alginate biomaterials [92]. Even after purification, lipoteichoic acid and LPS, the 
most commonly known endotoxin, can remain and are recognized by Toll-like 
Receptors (TLRs) [52]. It has been demonstrated that recognition of PAMPs by 
TLRs causes the activation of macrophages through the NF-κB pathway [105]. 
NF-κB results in the transcriptional upregulation of genes most associated with 
cytokine and chemokine production which serve to intensify humoral response 
[105]. Within a week, the initial acute inflammatory period transitions to a chronic 
inflammatory period.
The chronic inflammatory stage is characterized by the accumulation of 
lymphocytes and monocytes, among other mononuclear cells, in the tissue 
surrounding the alginate biomaterial [106, 107]. It was discovered in vitro that 
lymphocytes can adhere to alginate biomaterial surfaces, but when placed in 
co-cultures with macrophages, they appeared to attach predominantly to the 
macrophage rather than the alginate microcapsule surface [100]. Further research 
has suggested that macrophage adhesion and fusion to biomaterial surface is 
Alginates - Recent Uses of This Natural Polymer
10
assisted by T lymphocytes [100]. Both macrophages and lymphocytes secrete 
inflammatory mediators. Examples of these include cytokines IL-1β, IL-6, and 
TNFα and chemokines IL-8, MCP, MIP-1β, and ENA-78, all of which are known to 
activate and recruit inflammatory effector cells such as neutrophils, monocytes, 
T lymphocytes, and natural killer cells [100, 105]. Similarly, it was discovered 
that certain cytokine, chemokine levels, matrix metalloproteinases (MMPs) 
and tissue inhibitor MMPs (TIMP), fluctuated over time which suggests that T 
lymphocyte-macrophage interactions have the ability to facilitate the chronic 
inflammatory phase of the FBR [100, 108]. There have been in vivo studies that 
have shown active T cells in response to synthetic materials during an inflamma-
tory response; however, in vitro studies have shown a lack of lymphocyte response 
to alginate biomaterials [100, 109]. A novel focus of study regarding mitogens, 
which are functional groups on the surface of biomaterials, led to the hypothesis 
that they can possibly trigger lymphocytes via cross-linking of glycoproteins, but 
these mitogenic properties have not been observed [100]. The chronic inflamma-
tory period usually subsides 2 weeks after implantation and any longer periods 
of inflammation are usually the result of infection [100, 102]. A combination of 
granulation, fibroblast infiltration, and macrophage/fibroblast surface adhesion 
result in the final fibrotic encapsulation of alginate biomaterials.
5.3 Immuno-modulation of alginate hydrogels
To overcome the challenges of inflammation and fibrosis associated with 
the foreign body response after alginate hydrogels are implanted, researchers 
are currently trying to establish technologies for potential immune modulation. 
Research into alginate immune-modulation methods currently involves the use 
of bioactive nanoparticles, immune regulatory cells, hydrogel surface topogra-
phy, and passive non-fouling agents [110]. In the past bioactive nanoparticles, 
like ketoprofen, have shown potential to modulate the degree of inflammation 
during FBR [111]. A recent study was able to load monoclonal antibody IgM 
nanoparticles during alginate encapsulation of pancreatic islets. This resulted 
in localized controlled release of the monoclonal antibody after implanta-
tion which decreased the immune response against transplants [112]. An islet 
transplantation study using the anti-inflammatory nanoparticle rapamycin, 
demonstrated reduced fibrosis and sustained glycemic control improvement 
[113]. Mesenchymal-derived stem cells have been shown to have a wide range of 
regenerative effects on several tissue injury types because of their multipotent 
capacity [114]. Several recent studies have demonstrated immune modulation 
of alginate hydrogels through co-delivery of MSCs with cell-delivery systems. 
This can help reduces inflammation and can modulate T-cell toxicity while also 
boosting wound healing properties and blood vessel formation of the graft site 
[115–117]. A better understanding of the mechanism of FBR in the future will 
help improve immune modulation technologies for transplantations involving 
alginate hydrogels.
6. Clinical relevance of alginate-based biomaterials
6.1 Type 1 diabetes mellitus treatment
While extensively performed in animal models for several decades, islet 
xenotransplantations have taken more time in advancing to clinical human 
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studies around the world. This is because the area of xenografts in general is 
still a highly regulated area in the transplantation field and is being studied 
heavily in animal models [118, 119]. In the United States, the stringent FDA 
regulations for all xenotransplantations has provided certain standards which 
must be achieved pre-clinically before moving to clinical trials [120]. This has 
made initiation of clinical trials involving alginate xenografts very slow in the 
United States. Nonetheless, here have recently been a small amount of clinical 
islet xenotransplantation trials that have been conducted outside of the US using 
porcine islet xenografts to treat IDDM in human subjects (Table 1). The first 
phase I/IIa clinical trial saw 7 T1DM patients receive up to 3 implantations of 
encapsulated neonatal porcine islets which resulted in 5 patients with improved 
blood glucose levels and two patients which achieved insulin independence for 
up to 32 weeks post-transplantation [121, 122]. From 2000 to 2003 in a clinical 
trial in Mexico, two cohorts totaling 21 IDDM patients underwent xenograft 
implantation of a collagen-covered pre-vascularized scaffold which housed 
250,000 islets with 30,000–100,000 Sertoli cells. After the first transplanta-
tion HbA1C showed significant reductions, with decreases in exogenous insulin 
demands observed for up to 4 years, and glucose stimulated C-peptide detected 
in urine for up to 4 years; in addition, zoonotic transmission of porcine microor-
ganisms was not detected for the duration of the study [123–125]. Unfortunately, 
the human clinical trial in Mexico did not include a control population under 
exogenous insulin therapy that could further validate the results [121]. In 
patients who received a steroid-based regimen 33–62% decrease in insulin 
requirements for up to 1 year with detectable presence of porcine C-peptide 
compared to two patients, which received steroid-free regimen, who saw change 
in IDDM conditions [126]. A comprehensive 2011 study, 14 IDDM patients 
were given 5000–20,000 IE/kg intraperitoneally via laparoscopy using wild-
type pre-weaned juvenile porcine islets without immunosuppressive therapy 
for 52 weeks [127]. Overall, 8 of the 14 patients showed a moderate decrease in 
insulin administration and HbA1C levels. A nonsignificant reduction in severe 
hypoglycemic events, or unaware hypoglycemic episodes, was also observed in 
the same patients [127, 128]. Alginate-based macrodevices have been the topic 
of heavy research since the late 1940s and recently have been tested clinically 
as a scaffold for therapeutic islet-delivery [115]. Patients with T1D have been 
subcutaneously implanted with macroencapsulated, bioartificial pancreatic βAir 
(BetaO2 Technologies Ltd., Israel) device; the study designed to monitor for 
180 days post-transplantation followed by removal of the device, and 6 months 
of follow-up afterwards. The device involved oxygen pumps which allowed for 
daily refueling of oxygen to devices while in-vivo. For the duration of the study, 
islets in the device did not face any immune rejection and survived to time of 
explant. Although there were no rejections in the body, the overall efficacy of the 
islets was low and metabolic control was absent; C-peptide levels were detected 
on day 1 of post-transplantation in all patients (range 0.028–0.093 nmol/L) 
and remained detectable up until 2–4 weeks but for one patient detectable up 
to 3 months post-transplantation [129, 130]. Continued research into alginate 
immune-isolation of pancreatic islet xenografts will continue to develop and will 
be tested clinically in the future.
6.2 Wound healing treatment
Alginate has shown effectiveness as a constituent of acellular matrix skin grafts 
to reduce wound healing duration, which is especially poor with diabetic patients 
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Number 
of 
subjects 
(n)
Porcine islet 
types used
Number 
of islets 
transplanted/
kg of body 
weight
Transplantation 
site
Study outcome Reference
12 Neonatal + 
Sertoli cells 
encapsulated 
in scaffold
14,000–21,000 Scaffold in 
subcutaneous 
space
• Deceased 
exog-
enous insulin 
requirement 
for up to 4 
years (50%)
• No serum 
C-peptide 
detected
[124, 125]
7 Encapsulated 
neonatal
5000–1000 Intraperitoneal 
space
• Two patients 
achieve 
independence 
for 32 weeks
• 6 Patients 
demonstrate 
lower HBA1c
[154]
1 Encapsulated 
fetal
15,000 Intraperitoneal 
space
• -12-week 
period of 30% 
reduction 
in insulin 
requirement
• Improvement 
in glycemic 
control for 14 
weeks
• Detectable 
C-peptide for 
11 months
• Live Islet 
detected for 
9.5 years
[127]
14 Encapsulated 
pre-weaned
5000–20,000 Intraperitoneal 
space
• Moderate 
decrease 
in insulin 
requirement 
in 57% of 
patients
• Major 
reduction in 
hypoglycemic 
episodes
[127]
8 Encapsulated 
pre-weaned
5000–20,000 Intraperitoneal 
space
Patients that 
received 
20,000/kg 
maintain 7% 
HbA1c for 600 
days. Reduced 
Hypoglycemic 
events
[123]
Table 1. 
Selected clinical encapsulated islet xenotransplantations in humans. IE is used to denote islet equivalents that 
make up the graft which are implanted during transplantation.
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[131–133]. A large multicenter study involving 75 patients with 100 wounds (50% 
UT grade 3 wounds) was conducted using an alginate containing GraftJacket® 
matrix skin graft. The study resulted in 91% of complete wound closure averaging 
around 9.6 weeks indicating the graft was a safe option for complex lower extremity 
wounds [134]. Recent clinical studies with an alginate containing skin graft known 
as AlloPatch® have shown the effectiveness in wound healing even when elevated 
HbA1C levels witnessed in one patient [135]. Several alginate-based skin grafts 
are commercially available for advanced wound healing which include Nu-Gel® 
(Systagenix), Tegagel® (3M GmbH)), Curasorb® Alginate (Medtronic), Sorbsan® 
(B. Braun Melsungen AG), and Kendall™ Hydrocolloid Dressing (Medtronic) 
[136]. Advances in the development of alginate matrices will continue to contribute 
to skin regeneration therapy improvements in the future.
6.3 Clinical uses in dentistry
The hydrophilic nature of alginate along with hydrogel forming and biocompat-
ible nature has made it a staple hydrocolloid for application in the field of dentistry 
[137]. Alginate-based gels have traditionally been used in dentistry to provide 
the dentist with impressions of teeth and bitemarks which can then be used as a 
template for dental implants [138–140]. Alginate is frequently used in clinical trials 
to obtain impressions when comparing various dental procedures [141–144]. In a 
recent clinical trial, silicone was found to be favored among patients in terms of 
comfortability although alginate impressions were found to be a cheaper procedure 
option [145, 146]. Alginate-containing matrices have also been tested for advanced 
periodontitis treatment, when compared to the normal 0.2% chlorhexidine treat-
ment alginate-containing Emdogain® saw significant reduction in plaque viability 
[147]. These alginate-containing enamel matrices have also shown significant clini-
cal regenerative capabilities for periodontal disease symptoms such as intrabony 
defects and gingival recession [148, 149].
7. Future direction for alginate-based biotechnologies
The development and use of alginate macro/micro devices for implantation 
have met both improvements and challenges. Specifically, alginate has been used 
in the production of microcapsules as well as scaffolds as a way to implant encap-
sulated islet cells in vivo. The use of natural polymers such as alginate introduces 
immunogenic and foreign body responses, which impact the functionality of the 
device over time [150]. For example, the mechanical integrity or structure of the 
device could be compromised, or it can decompose while inside the recipient. 
As a potential solution, alginate can be chemically modified so its properties can 
be better controlled against inflammatory response and mechanical stress [151]. 
This chemical modification includes both ionic and covalent crosslinks within 
alginate polymers which will increase the mechanical stability of both scaffolds 
and microcapsules [151]. This method of using two types of crosslinking to 
create the microbeads compared to using only covalent crosslinking has shown 
results of greater stability of these microcapsules within cells after weeks follow-
ing implantation [151]. Furthermore, in the long run, purification techniques 
of alginate hydrogels can be improved to decrease PAMP concentration which 
would help reduce FBR [92]. Purifying alginate gels of PAMPs can be difficult 
for those with a high G content, which are stronger and more viscous. However, 
the use of chemical extraction or dialysis methods as well as specific purifica-
tion methods would be required to remove these molecules. Another potential 
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solution to overcome graft failure is to use smaller islet cell graft volumes with 
vascularized membranes to produce stable neovascularization near the grafted 
tissue [152]. Using a macroencapsulation device such as TheraCyte and loading 
it with islet cells of smaller volume can increase blood supply near the site of 
encapsulation [152].
Given the molecular composition of alginate and its ability to crosslink and 
form hydrogels, this biomaterial can be used in an array of medical and clinical 
applications. Unfortunately, the implantation of alginate induces an immune 
response of the host, producing setbacks that current labs are attempting to solve. 
Because of both macrophages mediated and T-cell mediated immune response, 
the alginate macro/micro device loses its viability and long-term function once 
it is implanted in the host. Strategies aiming to reduce or prevent fibrosis on 
alginate encapsulated cells present conflicting results. Newly developed capsules 
contain alginate without a polycation layer shown improvement potential because 
the pro-inflammatory characteristic of polycations have been connected to 
fibrotic growth around capsules [153]. For alginate beads, removing the polyca-
tion layer can lead to less stability and more permeability to cytokines and growth 
factors [153].
Currently, the main focus regarding implantable alginate hydrogels is to address 
problems such as immune response, adequate sources of oxygen, and fibrosis. 
As more alginate-based devices are being brought into clinical application, these 
strategies among others should be considered and pursued for current and future 
alginate-based device production.
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